Study supports monovalent antibody in neuropsychiatric disease
New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model. The company says the findings support the continued clinical development… Read More